Tirzepatide protects against doxorubicin-induced cardiotoxicity by inhibiting oxidative stress and inflammation via PI3K/Akt signaling

Tirzepatide Once Weekly for the Treatment of Obesity

Ania M. Jastreboff, Louis J. Aronne, Nadia N. Ahmad et al. · New England Journal of Medicine · 2022 · 3.2K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

Juan P. Frías, Michael A. Nauck, Joanna Van et al. · The Lancet · 2018 · 799 citations

Medicine, Endocrinology, Pharmacology +17

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

Stefano Del Prato, Steven E. Kahn, Imre Pávó et al. · The Lancet · 2021 · 642 citations

Medicine, Pharmacology, Pharmacotherapy +16

FNDC5 alleviates oxidative stress and cardiomyocyte apoptosis in doxorubicin-induced cardiotoxicity via activating AKT

Xin Zhang, Can Hu, Chun‐Yan Kong et al. · Cell Death and Differentiation · 2019 · 449 citations · Full text

Life Sciences, Cell Biology, Pharmacology +17

Matrine attenuates oxidative stress and cardiomyocyte apoptosis in doxorubicin-induced cardiotoxicity via maintaining AMPKα/UCP2 pathway

Can Hu, Xin Zhang, Wenying Wei et al. · Acta Pharmaceutica Sinica B · 2019 · 255 citations · Full text

Life Sciences, Cardiology, Pharmacology +17